Anti-retroviral Drugs Market, By Product Type, By Application, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2023-2030
보고서 하이라이트
항레트로바이러스 약 시장 규모는 2022년 397억 9,420만 달러로 평가되었고 2023년부터 2030년까지 복합 연간 성장률(CAGR) 5.1%로 확대될 전망입니다
항 레트로 바이러스 약물 시장 - 시장 역학
HIV에 대한 부담 증가, 연구개발(R&D)에 대한 투자 증가, 보다 효과적인 신약의 가용성이 시장 수요를 촉진할 것으로 예상됩니다.
분석 대상 시장의 성장은 HIV 부담 증가, R&D(R&D) 투자 확대, 보다 효과적인 신약 가용성 등 몇 가지 주요 요인에 의해 추진됩니다. 예를 들어 인도의 HIV 추정 팩트 시트는 2021년 연간 신규 감염자 수(ANI)가 6만 2,970명으로 추정된다고 보고했습니다. 또한 세계보건기구(WHO)는 2022년 7월, 2021년에는 3,840만 명이 HIV와 함께 생활하고 있다고 보고했습니다. 특히 아프리카은 여전히 심각한 영향을 받고 있으며, 성인의 약 25명 중 1명(3.4%)이 HIV에 감염되어 세계 HIV 감염자 수의 3분의 2 이상을 차지하고 있습니다. WHO는 또한 지난 20년간 HIV 감염자의 32.8% 증가를 강조했습니다. 그 결과 HIV의 만연이 항레트로바이러스 약물 수요에 박차를 가하고 있습니다.
또한 다양한 제약 기업에 의한 R&D 투자 증가가 시장 성장의 원동력이 되고 있습니다. 그 예로 6월 GSK(그락소 스미스크라인)는 감염증, 특히 저소득 국가에 불균형한 영향을 미치는 감염증 치료를 위한 연구개발 활동 가속화를 목표로 10억 유로의 엄청난 투자를 발표했습니다. GSK의 연구개발은 HIV(비브헬스케어를 통해), 말라리아, 결핵, 기타 감염증을 포함한 다양한 질병을 예방·치료하기 위한 새롭고 혁신적인 백신과 의약품의 개발에 중점을 두고 있습니다. 이러한 질병은 저소득국의 대부분으로 질병 부담의 60% 이상을 차지하고 있습니다. GSK의 세계 건강 R&D 허브는 항레트로바이러스 약물 조사를 포함하여 13개의 고부담 감염을 대상으로 30개 이상의 신규 백신과 신약의 가능성을 추진하고 있습니다. 그 결과 연구개발 투자의 증대가 연구시장 확대의 큰 원동력이 되고 있습니다.
항 레트로 바이러스 약물 시장 - 주요 인사이트
우리의 리서치 애널리스트의 분석에 따르면 세계 항 레트로 바이러스 약물 시장은 예측 기간(2023년-2030년)에 복합 연간 성장률(CAGR) 약 5.1%로 매년 성장할 것으로 예측됩니다.
항레트로바이러스 약물 시장은 HIV 부담 증가, 연구 개발(R&D) 투자 증가, 보다 효과적인 신약 가용성 등을 배경으로 현저한 속도로 성장할 것으로 예측됩니다.
제품 유형별로는 뉴클레오시드계 역전사효소 억제제(NRTI)와 비뉴클레오시드계 역전사효소 억제제(NNRTI)가 2022년 최대 시장 점유율을 나타낼 것으로 예측됩니다.
용도별로는 HIV/AIDS가 2022년의 주요 부문입니다
지역별로는 북미가 2022년 매출을 선도
항 레트로 바이러스 약물 시장 - 세분화 분석 :
세계 항레트로바이러스 약물 시장은 제품 유형, 용도별, 지역별로 구분됩니다.
제품 유형에 따라 시장은 4개의 부문으로 나뉩니다: 프로테아제 억제제, 비뉴클레오시드계 역전사효소 억제제, 인테그라제 억제제, 뉴클레오시드 유사체 및 뉴클레오시드계 역전사효소 억제제입니다. 이 분류에서 뉴클레오시드 역전사효소 억제제(NRTI)와 비뉴클레오시드 역전사효소 억제제(NNRTI)가 두드러지며, 이 부문에 큰 성장 가능성을 가져왔습니다. NRTI는 역전사효소를 억제함으로써 작용하지만, NNRTI는 역전사효소에 결합하고 그 후에 변형합니다. 이 두 가지 메커니즘은 HIV가 자신을 복제하는 데 필요한 효소를 억제하기 때문에이 두 가지 유형은 바이러스와의 싸움에 특히 효과적입니다.
시장은 용도별로 4개의 부문으로 분류된다: 간염, HIV/AIDS, 헤르페스, 인플루엔자, 기유형니다. 특히 항 레트로 바이러스 약물은 HIV/ AIDS 치료에 널리 사용됩니다. 미국 보건사회 복지성의 보고에 의하면, 세계에서 약 3,720만명이 HIV/AIDS와 싸우고 있습니다.
항 레트로 바이러스 약물 시장 - 지리적 인사이트
지역적으로, 이 시장은 북미, 라틴아메리카, 유럽, 아시아태평양, 중동 및 아프리카 각 지역으로 퍼져 있습니다. 이 지역은 비즈니스를 제공하는 국가에 의해 더 나뉩니다.
항 레트로 바이러스 약물 시장 - 경쟁 구도 :
항 레트로 바이러스 약물 분야에서 기업은 주로 연구 개발 및 상업화에 주력하고 있습니다. 새로운 항레트로바이러스 요법의 발견과 생산, 기존 약물의 개선, 이들 약물의 안전성과 효능을 평가하기 위한 임상시험을 실시했습니다. 또한, 제약 회사는 종종 건강 관리 조직 및 정부 기관과 협력하여 감염 지역에서 항 레트로 바이러스 치료에 대한 접근을 확대하고 있습니다.
목차
제1장 항레트로바이러스 약 시장 개요
제2장 주요 요약
제3장 항레트로바이러스약의 주요 시장 동향
- 시장 성장 촉진요인
- 시장 성장 억제요인
- 시장 기회
- 향후 시장 동향
제4장 항레트로바이러스 약산업의 조사
- PEST 분석
- Porter's Five Forces 분석
- 성장 전망 맵핑
- 규제 틀의 분석
제5장 항레트로바이러스 약 시장 : COVID-19 감염증의 영향 분석
- 신형 코로나바이러스 감염증 이전의 영향 분석
- 신형 코로나바이러스 감염증 후의 영향 분석
제6장 항레트로바이러스 약 시장 상황
- 항레트로바이러스 약 시장 점유율 분석(2022년)
- 주요 제조업체별 분석 데이터
제7장 항레트로바이러스 약 시장 - 제품 유형별
- 개요
- 제품 유형별 부문 점유율 분석
- 프로테아제 억제제
- 비뉴클레오시드계 역전사효소 억제제
- 인테그라제 억제제
- 뉴클레오시드 유사체 및 뉴클레오시드 역전사효소 억제제
제8장 항레트로바이러스 약 시장 - 용도별
- 개요
- 용도별 부문 점유율 분석
- 간염
- HIV/에이즈
- 헤르페스
- 인플루엔자
- 기타
제9장 항레트로바이러스 약 시장 - 지역별
- 소개
- 북미
- 유럽
- 개요
- 유럽 주요 제조업체
- 독일
- 이탈리아
- 영국
- 프랑스
- 러시아
- 네덜란드
- 스웨덴
- 폴란드
- 기타
- 아시아태평양(APAC)
- 개요
- 아시아태평양 주요 제조업체
- 인도
- 중국
- 일본
- 한국
- 호주
- 태국
- 인도네시아
- 필리핀
- 기타
- 라틴아메리카
- 개요
- 라틴아메리카의 주요 제조업체
- 브라질
- 멕시코
- 아르헨티나
- 콜롬비아
- 기타
- 중동 및 아프리카
- 개요
- 중동 및 아프리카 주요 제조업체
- 사우디아라비아
- 아랍에미리트(UAE)
- 이스라엘
- 터키
- 알제리
- 이집트
- 기타
제10장 주요 벤더 분석 - 항레트로바이러스 약 업계
- 경쟁 대시보드
- 기업 프로파일
- AbbVie Inc.
- Boehringer Ingelheim International GmbH
- Bristol-Myers Squibb Company
- F. Hoffmann-La Roche Ltd
- Gilead Sciences, Inc.
- Merck &Co, Inc.
- Viatris Inc.(Mylan Inc.)
- GlaxoSmithKline plc(ViiV Healthcare)
- Cipla Inc.
- Johnson and Johnson
제11장 애널리스트의 전방위 전망
BJH
REPORT HIGHLIGHT
Anti-retroviral Drugs Market size was valued at USD 39,794.2 Million in 2022, expanding at a CAGR of 5.1% from 2023 to 2030.
Antiretroviral drugs are medications used to treat retroviral infections, with HIV (Human Immunodeficiency Virus) being the most prominent example. These drugs work by inhibiting the replication of the virus, thereby slowing down the progression of the disease and reducing the viral load in the body.
Anti-retroviral Drugs Market- Market Dynamics
The increasing burden of HIV, heightened investments in research and development (R&D), and the availability of more effective novel drugs is expected to propel the market demand
The growth of the analyzed market is propelled by several key factors, including the increasing burden of HIV, heightened investments in research and development (R&D), and the availability of more effective novel drugs. For example, in 2022, the HIV Estimates Factsheet for India reported an estimated annual new infection (ANI) of 62.97 thousand cases in 2021. Furthermore, the World Health Organization (WHO) reported in July 2022 that 38.4 million individuals were living with HIV in 2021. The African region, in particular, remains profoundly impacted, with approximately 1 in every 25 adults (3.4%) living with HIV and contributing to over two-thirds of the global HIV-infected population. WHO also highlighted a significant 32.8% increase in HIV cases over the past two decades. Consequently, the growing prevalence of HIV is fueling the demand for antiretroviral drugs.
Moreover, increased investments in R&D by various pharmaceutical companies are a driving force behind the market's growth. As an illustration, in June 2022, GSK (GlaxoSmithKline) announced a substantial EUR 1 billion investment aimed at accelerating R&D activities for the treatment of infectious diseases, particularly those disproportionately affecting lower-income countries. GSK's research endeavors focus on the development of new and innovative vaccines and medications to prevent and treat various diseases, including HIV (via ViiV Healthcare), malaria, tuberculosis, and other infectious diseases. These diseases collectively account for over 60% of the disease burden in many lower-income nations. GSK's Global Health R&D Hubs are advancing with over 30 potential new vaccines and medications, targeting 13 high-burden infectious diseases, including antiretroviral drug research. Consequently, the augmented R&D investments are a significant driving factor behind the expansion of the studied market.
Anti-retroviral Drugs Market- Key Insights
As per the analysis shared by our research analyst, the global Anti-retroviral Drugs Market is estimated to grow annually at a CAGR of around 5.1% over the forecast period (2023-2030)
The Anti-retroviral Drugs Market is projected to grow at a significant rate driven by the increasing burden of HIV, heightened investments in research and development (R&D), and the availability of more effective novel drugs
Based on product type, the Nucleoside Reverse Transcriptase Inhibitors (NRTIs) and Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) was predicted to show maximum market share in the year 2022
Based on Application, HIV/AIDS was the leading Segment in 2022
On the basis of region, North America was the leading revenue generator in 2022
Anti-retroviral Drugs Market- Segmentation Analysis:
The Global Anti-retroviral Drugs Market is segmented on the basis of Product Type, By Application, and Region.
Based on the type of product, the market is divided into four segments: Protease Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Integrase Inhibitors, and Nucleoside Analogs and Nucleoside Reverse Transcriptase Inhibitors. Within this classification, Nucleoside Reverse Transcriptase Inhibitors (NRTIs) and Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) stand out prominently, offering significant growth potential to this segment. NRTIs function by blocking reverse transcriptase, while NNRTIs bind to and subsequently modify reverse transcriptase. This dual mechanism interferes with the enzyme HIV requires to replicate itself, rendering these two types particularly effective in combating the virus.
The market is categorized by application into four segments: Hepatitis, HIV/AIDS, Herpes, Influenza, and Others. Notably, anti-retroviral drugs find extensive usage in the treatment of HIV/AIDS, primarily due to the substantial global prevalence of this disease. According to reports from the US Department of Health & Human Services, approximately 37.2 million individuals worldwide are grappling with HIV/AIDS.
Anti-retroviral Drugs Market- Geographical Insights
Geographically, this market is widespread into the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business.
Anti-retroviral Drugs Market- Competitive Landscape:
In the field of antiretroviral drugs, companies are primarily focused on research, development, and commercialization. They work on discovering and producing new antiretroviral therapies, improving existing medications, and conducting clinical trials to assess the safety and efficacy of these drugs. Additionally, pharmaceutical companies often collaborate with healthcare organizations and government agencies to expand access to antiretroviral treatments in affected regions.
Recent Developments:
In September 2022, Merck announced the commencement of a new phase 3 clinical trial to assess the efficacy of once-daily oral islatravir for the treatment of HIV-1 infection.
In August 2022, Gilead obtained global regulatory approval for Sunlenca (Lenacapavir), a unique twice-yearly treatment option for HIV.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL ANTI-RETROVIRAL DRUGS MARKET KEY PLAYERS
- AbbVie Inc.
- Boehringer Ingelheim International GmbH
- Bristol-Myers Squibb Company
- F. Hoffmann-La Roche Ltd
- Gilead Sciences, Inc.
- Merck & Co, Inc.
- Viatris Inc. (Mylan Inc.)
- GlaxoSmithKline plc (ViiV Healthcare)
- Cipla Inc.
- Johnson and Johnson
GLOBAL ANTI-RETROVIRAL DRUGS MARKET, BY PRODUCT TYPE
- Protease Inhibitors
- Non-Nucleoside Reverse Transcriptase Inhibitors
- Integrase Inhibitors
- Nucleoside Analogs and Nucleoside Reverse Transcriptase Inhibitors
GLOBAL ANTI-RETROVIRAL DRUGS MARKET, BY APPLICATION
- Hepatitis
- HIV/AIDS
- Herpes
- Influenza
- Others
GLOBAL ANTI-RETROVIRAL DRUGS MARKET, BY REGION
- North America
- The U.S.
- Canada
- Europe
- Germany
- France
- Italy
- Spain
- United Kingdom
- Russia
- Netherlands
- Sweden
- Poland
- Rest of Europe
- Asia Pacific
- India
- China
- South Korea
- Japan
- Australia
- Thailand
- Indonesia
- Philippines
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
- The Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Israel
- Turkey
- Algeria
- Egypt
- Rest of MEA
Table of Contents
1. Anti-retroviral Drugs Market Overview
- 1.1. Study Scope
- 1.2. Market Estimation Years
2. Executive Summary
- 2.1. Market Snippet
- 2.1.1. Anti-retroviral Drugs Market Snippet by Product Type
- 2.1.2. Anti-retroviral Drugs Market Snippet by Application
- 2.1.3. Anti-retroviral Drugs Market Snippet by Country
- 2.1.4. Anti-retroviral Drugs Market Snippet by Region
- 2.2. Competitive Insights
3. Anti-retroviral Drugs Key Market Trends
- 3.1. Anti-retroviral Drugs Market Drivers
- 3.1.1. Impact Analysis of Market Drivers
- 3.2. Anti-retroviral Drugs Market Restraints
- 3.2.1. Impact Analysis of Market Restraints
- 3.3. Anti-retroviral Drugs Market Opportunities
- 3.4. Anti-retroviral Drugs Market Future Trends
4. Anti-retroviral Drugs Industry Study
- 4.1. PEST Analysis
- 4.2. Porter's Five Forces Analysis
- 4.3. Growth Prospect Mapping
- 4.4. Regulatory Framework Analysis
5. Anti-retroviral Drugs Market: COVID-19 Impact Analysis
- 5.1. Pre-COVID-19 Impact Analysis
- 5.2. Post-COVID-19 Impact Analysis
- 5.2.1. Top Performing Segments
- 5.2.2. Marginal Growth Segments
- 5.2.3. Top Looser Segments
- 5.2.4. Marginal Loss Segments
6. Anti-retroviral Drugs Market Landscape
- 6.1. Anti-retroviral Drugs Market Share Analysis, 2022
- 6.2. Breakdown Data, by Key Manufacturer
- 6.2.1. Established Players' Analysis
- 6.2.2. Emerging Players' Analysis
7. Anti-retroviral Drugs Market - By Product Type
- 7.1. Overview
- 7.1.1. Segment Share Analysis, By Product Type, 2022 & 2030 (%)
- 7.1.2. Protease Inhibitors
- 7.1.3. Non-Nucleoside Reverse Transcriptase Inhibitors
- 7.1.4. Integrase Inhibitors
- 7.1.5. Nucleoside Analogs and Nucleoside Reverse Transcriptase Inhibitors
8. Anti-retroviral Drugs Market - By Application
- 8.1. Overview
- 8.1.1. Segment Share Analysis, By Application, 2022 & 2030 (%)
- 8.1.2. Hepatitis
- 8.1.3. HIV/AIDS
- 8.1.4. Herpes
- 8.1.5. Influenza
- 8.1.6. Others
9. Anti-retroviral Drugs Market- By Geography
- 9.1. Introduction
- 9.1.1. Segment Share Analysis, By Geography, 2022 & 2030 (%)
- 9.2. North America
- 9.2.1. Overview
- 9.2.2. Anti-retroviral Drugs Key Manufacturers in North America
- 9.2.3. North America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
- 9.2.4. North America Market Size and Forecast, By Product Type, 2018 - 2030 (US$ Million)
- 9.2.5. North America Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
- 9.2.6. U.S.
- 9.2.6.1. Overview
- 9.2.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
- 9.2.6.3. U.S. Market Size and Forecast, By Product Type, 2018 - 2030 (US$ Million)
- 9.2.6.4. U.S. Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
- 9.2.7. Canada
- 9.2.7.1. Overview
- 9.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
- 9.2.7.3. Canada Market Size and Forecast, By Product Type, 2018 - 2030 (US$ Million)
- 9.2.7.4. Canada Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
- 9.3. Europe
- 9.3.1. Overview
- 9.3.2. Anti-retroviral Drugs Key Manufacturers in Europe
- 9.3.3. Europe Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
- 9.3.4. Europe Market Size and Forecast, By Product Type, 2018 - 2030 (US$ Million)
- 9.3.5. Europe Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
- 9.3.6. Germany
- 9.3.6.1. Overview
- 9.3.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
- 9.3.6.3. Germany Market Size and Forecast, By Product Type, 2018 - 2030 (US$ Million)
- 9.3.6.4. Germany Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
- 9.3.7. Italy
- 9.3.7.1. Overview
- 9.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
- 9.3.7.3. Italy Market Size and Forecast, By Product Type, 2018 - 2030 (US$ Million)
- 9.3.7.4. Italy Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
- 9.3.8. United Kingdom
- 9.3.8.1. Overview
- 9.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
- 9.3.8.3. United Kingdom Market Size and Forecast, By Product Type, 2018 - 2030 (US$ Million)
- 9.3.8.4. United Kingdom Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
- 9.3.9. France
- 9.3.9.1. Overview
- 9.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
- 9.3.9.3. France Market Size and Forecast, By Product Type, 2018 - 2030 (US$ Million)
- 9.3.9.4. France Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
- 9.3.10. Russia
- 9.3.10.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
- 9.3.10.2. Russia Market Size and Forecast, By Product Type, 2018 - 2030 (US$ Million)
- 9.3.10.3. Russia Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
- 9.3.11. Netherlands
- 9.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
- 9.3.11.2. Netherlands Market Size and Forecast, By Product Type, 2018 - 2030 (US$ Million)
- 9.3.11.3. Netherlands Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
- 9.3.12. Sweden
- 9.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
- 9.3.12.2. Sweden Market Size and Forecast, By Product Type, 2018 - 2030 (US$ Million)
- 9.3.12.3. Sweden Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
- 9.3.13. Poland
- 9.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
- 9.3.13.2. Poland Market Size and Forecast, By Product Type, 2018 - 2030 (US$ Million)
- 9.3.13.3. Poland Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
- 9.3.14. Rest of Europe
- 9.3.14.1. Overview
- 9.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
- 9.3.14.3. Rest of the Europe Market Size and Forecast, By Product Type, 2018 - 2030 (US$ Million)
- 9.3.14.4. Rest of the Europe Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
- 9.4. Asia Pacific (APAC)
- 9.4.1. Overview
- 9.4.2. Anti-retroviral Drugs Key Manufacturers in Asia Pacific
- 9.4.3. Asia Pacific Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
- 9.4.4. Asia Pacific Market Size and Forecast, By Product Type, 2018 - 2030 (US$ Million)
- 9.4.5. Asia Pacific Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
- 9.4.6. India
- 9.4.6.1. Overview
- 9.4.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
- 9.4.6.3. India Market Size and Forecast, By Product Type, 2018 - 2030 (US$ Million)
- 9.4.6.4. India Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
- 9.4.7. China
- 9.4.7.1. Overview
- 9.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
- 9.4.7.3. China Market Size and Forecast, By Product Type, 2018 - 2030 (US$ Million)
- 9.4.7.4. China Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
- 9.4.8. Japan
- 9.4.8.1. Overview
- 9.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
- 9.4.8.3. Japan Market Size and Forecast, By Product Type, 2018 - 2030 (US$ Million)
- 9.4.8.4. Japan Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
- 9.4.9. South Korea
- 9.4.9.1. Overview
- 9.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
- 9.4.9.3. South Korea Market Size and Forecast, By Product Type, 2018 - 2030 (US$ Million)
- 9.4.9.4. South Korea Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
- 9.4.10. Australia
- 9.4.10.1. Overview
- 9.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
- 9.4.10.3. Australia Market Size and Forecast, By Product Type, 2018 - 2030 (US$ Million)
- 9.4.10.4. Australia Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
- 9.4.11. Thailand
- 9.4.11.1. Overview
- 9.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
- 9.4.11.3. Thailand Market Size and Forecast, By Product Type, 2018 - 2030 (US$ Million)
- 9.4.11.4. Thailand Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
- 9.4.12. Indonesia
- 9.4.12.1. Overview
- 9.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
- 9.4.12.3. Indonesia Market Size and Forecast, By Product Type, 2018 - 2030 (US$ Million)
- 9.4.12.4. Indonesia Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
- 9.4.13. Philippines
- 9.4.13.1. Overview
- 9.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
- 9.4.13.3. Philippines Market Size and Forecast, By Product Type, 2018 - 2030 (US$ Million)
- 9.4.13.4. Philippines Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
- 9.4.14. Rest of APAC
- 9.4.14.1. Overview
- 9.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
- 9.4.14.3. Rest of APAC Market Size and Forecast, By Product Type, 2018 - 2030 (US$ Million)
- 9.4.14.4. Rest of APAC Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
- 9.5. Latin America
- 9.5.1. Overview
- 9.5.2. Anti-retroviral Drugs Key Manufacturers in Latin America
- 9.5.3. Latin America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
- 9.5.4. Latin America Market Size and Forecast, By Product Type, 2018 - 2030 (US$ Million)
- 9.5.5. Latin America Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
- 9.5.6. Brazil
- 9.5.6.1. Overview
- 9.5.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
- 9.5.6.3. Brazil Market Size and Forecast, By Product Type, 2018 - 2030 (US$ Million)
- 9.5.6.4. Brazil Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
- 9.5.7. Mexico
- 9.5.7.1. Overview
- 9.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
- 9.5.7.3. Mexico Market Size and Forecast, By Product Type, 2018 - 2030 (US$ Million)
- 9.5.7.4. Mexico Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
- 9.5.8. Argentina
- 9.5.8.1. Overview
- 9.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
- 9.5.8.3. Argentina Market Size and Forecast, By Product Type, 2018 - 2030 (US$ Million)
- 9.5.8.4. Argentina Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
- 9.5.9. Colombia
- 9.5.9.1. Overview
- 9.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
- 9.5.9.3. Colombia Market Size and Forecast, By Product Type, 2018 - 2030 (US$ Million)
- 9.5.9.4. Colombia Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
- 9.5.10. Rest of LATAM
- 9.5.10.1. Overview
- 9.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
- 9.5.10.3. Rest of LATAM Market Size and Forecast, By Product Type, 2018 - 2030 (US$ Million)
- 9.5.10.4. Rest of LATAM Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
- 9.6. Middle East and Africa
- 9.6.1. Overview
- 9.6.2. Anti-retroviral Drugs Key Manufacturers in Middle East and Africa
- 9.6.3. Middle East and Africa Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
- 9.6.4. Middle East and Africa Market Size and Forecast, By Product Type, 2018 - 2030 (US$ Million)
- 9.6.5. Middle East and Africa Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
- 9.6.6. Saudi Arabia
- 9.6.6.1. Overview
- 9.6.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
- 9.6.6.3. Saudi Arabia Market Size and Forecast, By Product Type, 2018 - 2030 (US$ Million)
- 9.6.6.4. Saudi Arabia Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
- 9.6.7. United Arab Emirates
- 9.6.7.1. Overview
- 9.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
- 9.6.7.3. United Arab Emirates Market Size and Forecast, By Product Type, 2018 - 2030 (US$ Million)
- 9.6.7.4. United Arab Emirates Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
- 9.6.8. Israel
- 9.6.8.1. Overview
- 9.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
- 9.6.8.3. Israel Market Size and Forecast, By Product Type, 2018 - 2030 (US$ Million)
- 9.6.8.4. Israel Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
- 9.6.9. Turkey
- 9.6.9.1. Overview
- 9.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
- 9.6.9.3. Turkey Market Size and Forecast, By Product Type, 2018 - 2030 (US$ Million)
- 9.6.9.4. Turkey Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
- 9.6.10. Algeria
- 9.6.10.1. Overview
- 9.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
- 9.6.10.3. Algeria Market Size and Forecast, By Product Type, 2018 - 2030 (US$ Million)
- 9.6.10.4. Algeria Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
- 9.6.11. Egypt
- 9.6.11.1. Overview
- 9.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
- 9.6.11.3. Egypt Market Size and Forecast, By Product Type, 2018 - 2030 (US$ Million)
- 9.6.11.4. Egypt Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
- 9.6.12. Rest of MEA
- 9.6.12.1. Overview
- 9.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
- 9.6.12.3. Rest of MEA Market Size and Forecast, By Product Type, 2018 - 2030 (US$ Million)
- 9.6.12.4. Rest of MEA Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
10. Key Vendor Analysis- Anti-retroviral Drugs Industry
- 10.1. Competitive Dashboard
- 10.2. Company Profiles
- 10.2.1. AbbVie Inc.
- 10.2.2. Boehringer Ingelheim International GmbH
- 10.2.3. Bristol-Myers Squibb Company
- 10.2.4. F. Hoffmann-La Roche Ltd
- 10.2.5. Gilead Sciences, Inc.
- 10.2.6. Merck & Co, Inc.
- 10.2.7. Viatris Inc. (Mylan Inc.)
- 10.2.8. GlaxoSmithKline plc (ViiV Healthcare)
- 10.2.9. Cipla Inc.
- 10.2.10. Johnson and Johnson
11. 360 Degree Analyst View
12. Appendix
- 12.1. Research Methodology
- 12.2. References
- 12.3. Abbreviations
- 12.4. Disclaimer
- 12.5. Contact Us
